title: A mechanism of resistance to gefitinib mediated by cellular reprogramming and the acquisition of an FGF2-FGFR1 autocrine growth loop.
abstract: Despite initial and often dramatic responses of epidermal growth factor receptor (EGFR)-addicted lung tumors to the EGFR-specific tyrosine kinase inhibitors (TKIs), gefitinib and erlotinib, nearly all develop resistance and relapse. To explore novel mechanisms mediating acquired resistance, we employed non-small-cell lung cancer (NSCLC) cell lines bearing activating mutations in EGFR and rendered them resistant to EGFR-specific TKIs through chronic adaptation in tissue culture. In addition to previously observed resistance mechanisms including EGFR-T790M 'gate-keeper' mutations and MET amplification, a subset of the seven chronically adapted NSCLC cell lines including HCC4006, HCC2279 and H1650 cells exhibited marked induction of fibroblast growth factor (FGF) 2 and FGF receptor 1 (FGFR1) mRNA and protein. Also, adaptation to EGFR-specific TKIs was accompanied by an epithelial to mesenchymal transition (EMT) as assessed by changes in CDH1, VIM, ZEB1 and ZEB2 expression and altered growth properties in Matrigel. In adapted cell lines exhibiting increased FGF2 and FGFR1 expression, measures of growth and signaling, but not EMT, were blocked by FGFR-specific TKIs, an FGF-ligand trap and FGFR1 silencing with RNAi. In parental HCC4006 cells, cell growth was strongly inhibited by gefitinib, although drug-resistant clones progress within 10 days. Combined treatment with gefitinib and AZD4547, an FGFR-specific TKI, prevented the outgrowth of drug-resistant clones. Thus, induction of FGF2 and FGFR1 following chronic adaptation to EGFR-specific TKIs provides a novel autocrine receptor tyrosine kinase-driven bypass pathway in a subset of lung cancer cell lines that are initially sensitive to EGFR-specific TKIs. The findings support FGFR-specific TKIs as potentially valuable additions to existing targeted therapeutic strategies with EGFR-specific TKIs to prevent or delay acquired resistance in EGFR-driven NSCLC.
authors.affiliation: Department of Craniofacial Biology, School of Dental Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
authors.forename: K E
authors.initials: KE
authors.lastname: Ware
authors.forename: T K
authors.initials: TK
authors.lastname: Hinz
authors.forename: E
authors.initials: E
authors.lastname: Kleczko
authors.forename: K R
authors.initials: KR
authors.lastname: Singleton
authors.forename: L A
authors.initials: LA
authors.lastname: Marek
authors.forename: B A
authors.initials: BA
authors.lastname: Helfrich
authors.forename: C T
authors.initials: CT
authors.lastname: Cummings
authors.forename: D K
authors.initials: DK
authors.lastname: Graham
authors.forename: D
authors.initials: D
authors.lastname: Astling
authors.forename: A-C
authors.initials: AC
authors.lastname: Tan
authors.forename: L E
authors.initials: LE
authors.lastname: Heasley
references.citation: Proc Natl Acad Sci U S A. 2010 Aug 31;107(35):15535-40
references.pmid: 20713723
references.citation: Mol Cancer Ther. 2007 Jun;6(6):1683-91
references.pmid: 17541031
references.citation: Mol Pharmacol. 2009 Jan;75(1):196-207
references.pmid: 18849352
references.citation: Cancer Lett. 2011 Jan 1;300(1):66-78
references.pmid: 20980099
references.citation: Cancer Res. 2007 Aug 15;67(16):7807-14
references.pmid: 17699786
references.citation: Clin Cancer Res. 2007 May 1;13(9):2795-803
references.pmid: 17473213
references.citation: Cell. 2010 Apr 2;141(1):69-80
references.pmid: 20371346
references.citation: Bioorg Med Chem. 2005 Aug 15;13(16):4835-41
references.pmid: 15953730
references.citation: Nat Med. 2012 Apr 05;18(4):494-6
references.pmid: 22481406
references.citation: Clin Exp Metastasis. 2008;25(8):843-54
references.pmid: 18696232
references.citation: PLoS One. 2010 Nov 29;5(11):e14117
references.pmid: 21152424
references.citation: Cancer Res. 2005 Mar 1;65(5):1778-82
references.pmid: 15753374
references.citation: Clin Cancer Res. 2012 Jul 15;18(14):3880-8
references.pmid: 22573348
references.citation: N Engl J Med. 2010 Jun 24;362(25):2380-8
references.pmid: 20573926
references.citation: N Engl J Med. 2002 Jan 10;346(2):92-8
references.pmid: 11784875
references.citation: Cell. 2010 Apr 2;141(1):18-20
references.pmid: 20371339
references.citation: Annu Rev Med. 2008;59:429-42
references.pmid: 17716025
references.citation: Cell. 2012 Mar 16;148(6):1089-98
references.pmid: 22424221
references.citation: J Clin Invest. 2008 Jul;118(7):2609-19
references.pmid: 18568074
references.citation: Clin Cancer Res. 2011 Mar 15;17(6):1616-22
references.pmid: 21135146
references.citation: Clin Cancer Res. 2005 Jan 1;11(1):397-405
references.pmid: 15671571
references.citation: Annu Rev Pathol. 2011;6:49-69
references.pmid: 20887192
references.citation: Proc Natl Acad Sci U S A. 2007 Dec 26;104(52):20932-7
references.pmid: 18093943
references.citation: Drug Resist Updat. 2009 Aug-Oct;12(4-5):95-102
references.pmid: 19501013
references.citation: Oncogene. 2010 Apr 22;29(16):2346-56
references.pmid: 20118985
references.citation: Science. 2004 Jun 4;304(5676):1497-500
references.pmid: 15118125
references.citation: Oncogene. 2008 Aug 7;27(34):4702-11
references.pmid: 18408761
references.citation: Nat Genet. 2012 Jul 01;44(8):852-60
references.pmid: 22751098
references.citation: J Clin Oncol. 2012 Feb 1;30(4):433-40
references.pmid: 22215752
references.citation: Clin Cancer Res. 2008 May 15;14(10):2895-9
references.pmid: 18483355
references.citation: J Med Chem. 2011 Sep 22;54(18):6342-63
references.pmid: 21812414
references.citation: J Thorac Oncol. 2011 Jul;6(7):1152-61
references.pmid: 21597390
references.citation: Clin Cancer Res. 2013 Jan 1;19(1):279-90
references.pmid: 23091115
references.citation: Sci Transl Med. 2011 Mar 23;3(75):75ra26
references.pmid: 21430269
references.citation: Cancer Cell. 2010 Jan 19;17(1):77-88
references.pmid: 20129249
references.citation: Science. 2007 May 18;316(5827):1039-43
references.pmid: 17463250
references.citation: Clin Cancer Res. 2006 Dec 15;12(24):7232-41
references.pmid: 17189394
references.citation: N Engl J Med. 2004 May 20;350(21):2129-39
references.pmid: 15118073
references.citation: Clin Cancer Res. 2011 Aug 1;17(15):5016-25
references.pmid: 21673064
references.citation: ACS Med Chem Lett. 2011 Dec 8;2(12):907-912
references.pmid: 22247788
references.citation: Nat Rev Drug Discov. 2009 Sep;8(9):709-23
references.pmid: 19629074
references.citation: J Clin Oncol. 2007 Feb 10;25(5):587-95
references.pmid: 17290067
references.citation: Cancer Invest. 2012 Jun;30(5):433-46
references.pmid: 22571344
references.citation: Cancer Discov. 2012 Oct;2(10):934-47
references.pmid: 22961667
references.citation: J Clin Oncol. 2003 Oct 15;21(20):3798-807
references.pmid: 12953099
references.citation: Cancer Res. 2012 Apr 15;72(8):2045-56
references.pmid: 22369928